 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Samsung C&T and its bio subsidiaries are expanding their investments in global bio-innovation companies.
On July 11th, Samsung C&T, along with its subsidiaries Samsung Biologics and Samsung Bioepis, announced that they will invest in Flagship Pioneering’s 8th fund through the Life Science Fund II, established in collaboration with Samsung Venture Investment. The investment amount is 72 billion KRW. Flagship Pioneering's 8th fund focuses on AI-based drug development platform technologies and has a total fund size of 2.6 billion USD (approximately 3.6 trillion KRW).
Through this investment, Samsung aims to gain priority access to information on innovative life science technology companies identified by the 8th fund. Samsung plans to evaluate additional investment opportunities on a case-by-case basis, utilizing this as a strategic gateway for discovering new business ventures in the bio and healthcare sectors.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
